Mirum Pharamceuticals (MIRM) PT Raised to $39 at Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Mirum Pharamceuticals (MIRM) PT Raised to $62 at Evercore ISI
June 17, 2024 3:22 PM EDTEvercore ISI analyst Gavin Clark-Gartner raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $62.00 (from $53.00) while maintaining a Outperform rating.
The analyst comments "MIRM is one of the rare, profitable smallcaps in our coverage based on their base business alone (which... More
Mirum Pharamceuticals (MIRM) PT Raised to $64 at Citi
June 17, 2024 3:00 PM EDTCiti analyst David Lebowitz raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $64.00 (from $38.00) while maintaining a Buy rating.
The analyst comments "In todays call, Mirum highlighted that volixibat performance in both PSC & PBC beat expectations. Early best-in-disease itch... More
Mirum Pharamceuticals (MIRM) PT Raised to $57 at Morgan Stanley
June 17, 2024 1:37 PM EDTMorgan Stanley analyst Michael E Ulz raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $57.00 (from $53.00) while maintaining a Overweight rating.
The analyst comments "Interim Ph2b volixibat results better than expected, as robust activity observed in PBC and blinded analysis in... More
Stifel Reiterates Buy Rating on Mirum Pharamceuticals (MIRM)
June 17, 2024 10:28 AM EDTStifel analyst Dae Gon Ha reiterated a Buy rating and $48.00 price target on Mirum Pharamceuticals (NASDAQ: MIRM)
The analyst comments "Today's interim analyses for volixibat studies - primary biliary cholangitis (PBC; VANTAGE) and primary sclerosing cholangitis (PSC; VISTAS) - offer promising... More
